|

The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

RECRUITINGN/ASponsored by 4th Military Clinical Hospital with Polyclinic, Poland
Actively Recruiting
PhaseN/A
Sponsor4th Military Clinical Hospital with Polyclinic, Poland
Started2024-08-01
Est. completion2025-12-01
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06707532

Summary

The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation

Exclusion Criteria:

* Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.

Conditions8

General Anesthetic Drug Adverse ReactionHeart ArrhythmiaHeart DiseaseKidney Failure, AcuteMuscle RelaxationMyopathy; DrugsProjectionSuccinylcholine Sensitivity

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.